Harmony Biosciences Holdings, Inc. (HRMY) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$37.84

From 52W high−12.41%

Volume1.00M

Market cap$2.19B

P/E (TTM)12.0x

P/S (TTM)2.3x

Div yield—

Key dataOct 19, 2026

Open

$37.84

From 52W high

−12.41%

Volume

1.00M

Market cap

$2.19B

ValuationView details →

P/E (Fwd)

9.5x

EV/EBITDA

6.1x

P/E (TTM)

12.0x

RSI (14)

39.0

MomentumView details →

1D Return

−1.08%

YTD Return

+0.58%

SummaryUpdated Jun 1, 2026

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company founded in 2017 and based in Plymouth Meeting, Pennsylvania. The company went public in August 2020 and has established itself as a profitable biotechnology firm focused exclusively on developing and commercializing therapies for patients with rare neurological disorders. Since its founding, Harmony has built a robust pipeline of eight assets across three distinct therapeutic franchises, with its flagship product WAKIX generating over $2 billion in cumulative sales since launch.

Ask drillr about Harmony Biosciences Holdings, Inc. →

ValuationView details →

P/E (Fwd)

9.5x

P/E (TTM)

12.0x

EV/EBITDA

6.1x

EV/Sales

1.7x

P/S (TTM)

2.3x

P/B (TTM)

2.2x

ProfitabilityView details →

Gross Margin

75.42%

Net Margin

18.88%

EBITDA Margin

28.79%

ROE (TTM)

18.14%

ROA (TTM)

13.20%

Asset Turnover

0.73x

GrowthView details →

Revenue YoY

+24.25%

EPS YoY

−1.26%

FCF YoY

+37.17%

Revenue CAGR 3Y

+25.64%

EPS CAGR 3Y

−3.49%

EBITDA YoY

+4.28%

MomentumView details →

1D Return

−1.08%

YTD Return

+0.58%

1Y Return

+44.64%

RSI (14)

39.0

vs 50D SMA

−5.75%

vs 200D SMA

+8.66%

Capital & dividendView details →

Debt/Equity

0.15x

Current Ratio

3.48x

Quick Ratio

3.45x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$1.28

EPS Surprise

33.89%

Beats (12Q)

8/12

Next Q EPS Est

$1.06

Avg Surprise (4Q)

−13.48%

Rev Surprise

4.19%

Financials snapshotView financials →

Revenue (TTM)

959.90M

Net Income (TTM)

181.27M

Op. CF (TTM)

355.08M

Next earningsNov 3, 2026 →

Latest newsMore news →

Harmony Biosciences Holdings, Inc. shares fell Monday following the CEO transition announcement.7d ago

Harmony Biosciences Holdings, Inc. announced that CEO Jeffrey Dayno will transition out of the role at the end of the year.7d ago

Similar companies

Aurinia Pharmaceuticals Inc.AUPH Recursion Pharmaceuticals, Inc.RXRX Day One Biopharmaceuticals, Inc.DAWN Jiangsu Recbio Technology Co., Ltd.02179.HK Fortrea Holdings Inc.FTRE SELLAS Life Sciences Group, Inc.SLS Find similar companies →

Latest newsMore news →

Harmony Biosciences Holdings, Inc. shares fell Monday following the CEO transition announcement.7d ago Harmony Biosciences Holdings, Inc. announced that CEO Jeffrey Dayno will transition out of the role at the end of the year.7d ago Harmony Biosciences announced it will present a poster on its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia, at the 17th European Narcolepsy Days in Bern, Switzerland on October 2-3, 2026.18d ago